EP3833762A4 - Compositions oligonucléotidiques pour cibler ccr2 et csf1r et leurs utilisations - Google Patents

Compositions oligonucléotidiques pour cibler ccr2 et csf1r et leurs utilisations Download PDF

Info

Publication number
EP3833762A4
EP3833762A4 EP19846282.2A EP19846282A EP3833762A4 EP 3833762 A4 EP3833762 A4 EP 3833762A4 EP 19846282 A EP19846282 A EP 19846282A EP 3833762 A4 EP3833762 A4 EP 3833762A4
Authority
EP
European Patent Office
Prior art keywords
csf1r
oligonucleotide compositions
ccr2
targeting
targeting ccr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19846282.2A
Other languages
German (de)
English (en)
Other versions
EP3833762A1 (fr
Inventor
Tatiana I. NOVOBRANTSEVA
Kevin KAUFFMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verseau Therapeutics Inc
Original Assignee
Verseau Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verseau Therapeutics Inc filed Critical Verseau Therapeutics Inc
Publication of EP3833762A1 publication Critical patent/EP3833762A1/fr
Publication of EP3833762A4 publication Critical patent/EP3833762A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP19846282.2A 2018-08-09 2019-08-09 Compositions oligonucléotidiques pour cibler ccr2 et csf1r et leurs utilisations Pending EP3833762A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862716671P 2018-08-09 2018-08-09
PCT/US2019/045841 WO2020033791A1 (fr) 2018-08-09 2019-08-09 Compositions oligonucléotidiques pour cibler ccr2 et csf1r et leurs utilisations

Publications (2)

Publication Number Publication Date
EP3833762A1 EP3833762A1 (fr) 2021-06-16
EP3833762A4 true EP3833762A4 (fr) 2022-09-28

Family

ID=69413677

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19846282.2A Pending EP3833762A4 (fr) 2018-08-09 2019-08-09 Compositions oligonucléotidiques pour cibler ccr2 et csf1r et leurs utilisations

Country Status (4)

Country Link
US (1) US20210317461A1 (fr)
EP (1) EP3833762A4 (fr)
JP (1) JP2021534101A (fr)
WO (1) WO2020033791A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11642629B2 (en) * 2020-03-20 2023-05-09 Saudi Arabian Oil Company Multi-layer composite gas separation membranes, methods for preparation, and use
US20220025436A1 (en) * 2020-07-21 2022-01-27 Rutgers, The State University Of New Jersey Method and Kit For CCR2 Expression Profiling And Disease Stratification
DE112022000079T5 (de) * 2021-04-01 2023-06-15 Hayk Davtyan Genetische Modifikation von Säugetierzellen zur Verleihung von Resistenz gegen CSF1R-Antagonisten

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140200259A1 (en) * 2006-02-23 2014-07-17 Novartis Ag RNAi-MEDIATED INHIBITION OF SELECT RECEPTOR TYROSINE KINASES FOR TREATMENT OF PATHOLOGIC OCULAR NEOVASCULARIZATION-RELATED CONDITIONS

Family Cites Families (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8748A (en) 1852-02-17 Improvement in weighing-machines
US815A (en) 1838-06-30 Improved cooking-stove for summer
US7569A (en) 1850-08-13 Improvement in ship-ventilators
US575A (en) 1838-01-20 Benjamin iapham
US5047533A (en) 1983-05-24 1991-09-10 Sri International Acyclic purine phosphonate nucleotide analogs
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
ATE171185T1 (de) 1985-03-15 1998-10-15 Antivirals Inc Immunotestmittel für polynukleotid und verfahren
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
WO1989009221A1 (fr) 1988-03-25 1989-10-05 University Of Virginia Alumni Patents Foundation N-alkylphosphoramidates oligonucleotides
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5697248A (en) 1991-07-25 1997-12-16 The Whitaker Corporation Liquid level sensor
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
DE69422163T2 (de) 1993-02-19 2000-06-15 Nippon Shinyaku Co., Ltd. Glycerolderivat, vorrichtung und pharmazeutische zusammensetzung
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
EP1179340A3 (fr) 1994-09-30 2003-05-07 INEX Pharmaceutical Corp. Compositions d' introduction de substances polyanioniques dans des cellules
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
SE9600820D0 (sv) 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
EP0934330A1 (fr) 1996-07-24 1999-08-11 Michelle M. Hanna Analogues de nucleotides a bases protegees avec groupes thiol proteges
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6267987B1 (en) 1997-12-12 2001-07-31 Samyang Corporation Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake
US6517869B1 (en) 1997-12-12 2003-02-11 Expression Genetics, Inc. Positively charged poly(alpha-(omega-aminoalkyl)lycolic acid) for the delivery of a bioactive agent via tissue and cellular uptake
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
KR20010071279A (ko) 1998-05-20 2001-07-28 추후제출 간세포를 표적으로하는 폴리에틸렌 글리콜-접합된폴리-ｌ-리신 고분자로된 유전자 운반체
WO1999060855A1 (fr) 1998-05-26 1999-12-02 Icn Pharmaceuticals, Inc. Nouveaux nucleosides comportant une fraction sucre bicyclique
US6833361B2 (en) 1998-05-26 2004-12-21 Ribapharm, Inc. Nucleosides having bicyclic sugar moiety
BR9912070A (pt) 1998-07-13 2001-04-10 Expression Genetics Inc Análogo de poliéster de poli-l-lisina como um solúvel, veìculo de distribuição de gene biodegradável
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP1161554B1 (fr) 1999-03-18 2011-03-09 Exiqon A/S Detection de mutations dans des genes par des amorces de lna specifiques
US6761883B2 (en) 1999-06-29 2004-07-13 The Board Of Trustees Of The Leland Stanford Junior University Mammalian myeloid progenitor cell subsets
ATE373421T1 (de) 1999-06-29 2007-10-15 Univ Leland Stanford Junior Untereinheiten von myeloid-progenitorzellen von säugern
EP1210428B1 (fr) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, recepteur de b7-4, et son utilisation
HUP0202882A2 (en) 1999-08-23 2002-12-28 Dana Farber Cancer Inst Inc Novel b7-4 molecules and uses therefor
KR100942863B1 (ko) 1999-08-24 2010-02-17 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
WO2001078653A2 (fr) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Traitement du rejet de greffe au moyen d'inhibiteurs de la fonction ccr2
GB0016258D0 (en) 2000-07-03 2000-08-23 Amersham Pharm Biotech Uk Ltd Base analogues
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
DK1334109T3 (da) 2000-10-04 2006-10-09 Santaris Pharma As Forbedret syntese af purin-blokerede nukleinsyre-analoger
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
US7514099B2 (en) 2005-02-14 2009-04-07 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US7060809B2 (en) 2001-09-04 2006-06-13 Exiqon A/S LNA compositions and uses thereof
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
EP1536688B1 (fr) 2002-09-13 2011-12-28 The Board Of Trustees Of The Leland Stanford Junior University Cellule souche mammifere de megakaryocytes
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
CA2508660C (fr) 2002-12-23 2013-08-20 Wyeth Anticorps anti pd-1 et utilisations
WO2004069809A1 (fr) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Mercaptoimidazoles en tant qu'agonistes du recepteur ccr2
JP4777873B2 (ja) 2003-02-14 2011-09-21 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 親油性薬物送達ビヒクルおよびこれらの使用方法
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
CN1835679A (zh) 2003-06-16 2006-09-20 国立大学法人九州大学 人源免疫活性细胞的制备方法
EP2135619A1 (fr) 2003-12-10 2009-12-23 Millennium Pharmaceuticals, Inc. Anticorps humanisés anti-CCR2 et leurs procédés d'utilisation
WO2005062854A2 (fr) 2003-12-19 2005-07-14 University Of Cincinnati Polyamides pour administration d'acides nucleiques
WO2005101002A1 (fr) * 2004-04-13 2005-10-27 Bayer Healthcare Ag Agents diagnostiques et therapeutiques de maladies associees au recepteur 2 de c-c chimiokine (ccr2)
KR20070044805A (ko) 2004-04-15 2007-04-30 키아스마, 인코포레이티드 생물학적 장벽 투과를 촉진시킬 수 있는 조성물
US20070249691A1 (en) 2004-05-26 2007-10-25 Boeckx Gustaaf M Mercaptoimidazoles as Ccr2 Receptor Antagonists
JP4764426B2 (ja) 2004-06-07 2011-09-07 プロチバ バイオセラピューティクス インコーポレイティッド カチオン性脂質および使用方法
UA85597C2 (ru) 2004-06-25 2009-02-10 Янссен Фармацевтика Н.В. Четвертичные соли как антагонисты ccr2
US8057821B2 (en) 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
AU2006231452B2 (en) 2005-04-01 2011-05-26 Intezyne Technologies, Inc. Polymeric micelles for drug delivery
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US7368439B2 (en) 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
WO2007014008A2 (fr) 2005-07-22 2007-02-01 Glaxo Group Limted Inhibiteur benzenesulfonamide de recepteur de chimiokine ccr2
WO2007013085A1 (fr) 2005-07-26 2007-02-01 Hetero Drugs Limited Procede innovant pour analogues acycliques de nucleotide phosphonate
WO2007081879A2 (fr) 2006-01-05 2007-07-19 Novartis Ag Méthodes pour prévenir et traiter des métastases de cancer et des pertes osseuses associées à des métastases de cancer
EP1973493A2 (fr) 2006-01-12 2008-10-01 Massachusetts Institute of Technology Élastomères biodégradables
US20070197590A1 (en) 2006-01-31 2007-08-23 Demong Duane E Substituted dipiperidine ccr2 antagonists
MX2008014005A (es) 2006-05-03 2009-01-27 Baltic Technology Dev Ltd Agentes antisentido que combinan un oligonucleotido modificado con base fuertemente unida y nucleasa artificial.
US20090297502A1 (en) 2006-06-15 2009-12-03 Li Li Ccr2 antagonists for chronic organ transplantation rejection
US20100234364A1 (en) 2006-07-14 2010-09-16 Arindrajit Basak Ccr2 inhibitors and methods of use thereof
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
DE602007012261D1 (de) 2006-07-14 2011-03-10 Chemocentryx Inc Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atherosklerose
WO2008042973A2 (fr) 2006-10-03 2008-04-10 Alnylam Pharmaceuticals, Inc. Formulations contenant un lipide
BRPI0715299A2 (pt) 2006-10-05 2013-07-23 The Johns Hopkins University mÉtodo para preparar nanoparticulas polimÉricas, mÉtodod para preparar uma coposiÇço micelar, micelas polimÉricas reconstituÍveis, composiÇço polimÉrica bioativa de nanopartÍculas, mÉtodo para proporcionar um medicamento a um paciente e processo para preparar composiÇÕes de nanoparticulas polimÉricas
JP2010519203A (ja) 2007-02-16 2010-06-03 メルク・シャープ・エンド・ドーム・コーポレイション 生物活性分子の活性を強化するための組成物及び方法
WO2008109238A1 (fr) 2007-03-02 2008-09-12 Janssen Pharmaceutica N.V. Cyclopentylpipéridines substituées antagonistes du ccr2
US7678894B2 (en) 2007-05-18 2010-03-16 Helicos Biosciences Corporation Nucleotide analogs
EP2162538B1 (fr) 2007-05-22 2016-04-20 Arcturus Therapeutics, Inc. Oligoméres pour la thérapie
DK2175859T3 (da) 2007-07-12 2012-06-18 Chemocentryx Inc Kondenserede heteroarylpyridyl- og phenylbenzen-sulfonamider som ccr2-modulatorer til behandling af inflammation
PL2644594T3 (pl) 2007-09-28 2018-01-31 Pfizer Ukierunkowanie na komórki nowotworowe za pomocą nanocząstek
US20110262425A1 (en) 2007-12-12 2011-10-27 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
EA021422B1 (ru) 2008-06-16 2015-06-30 Бинд Терапьютикс, Инк. Полимерные наночастицы, содержащие терапевтическое средство, и способ их получения
HUE035770T2 (en) 2008-06-16 2018-05-28 Pfizer Process for the preparation of diblock copolymers functionalized with targeting material for use in the preparation of therapeutic nanoparticles
EA020753B1 (ru) 2008-06-16 2015-01-30 Бинд Терапьютикс, Инк. Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение
ES2414159T3 (es) 2008-06-23 2013-07-18 Janssen Pharmaceutica, N.V. Antagonistas de acrilamida piperidilo de CCR2
WO2010021865A1 (fr) 2008-08-18 2010-02-25 Merck Sharp & Dohme Corp. Nouvelles nanoparticules lipidiques et nouveaux composants pour l'administration d'acides nucléiques
SG10201701323TA (en) 2008-08-18 2017-04-27 Amgen Fremont Inc Antibodies to ccr2
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
SI2342226T1 (sl) 2008-09-26 2016-11-30 Dana-Farber Cancer Institute Inc. Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
CA3006395C (fr) 2008-11-07 2022-05-31 Massachusetts Institute Of Technology Lipidoides aminoalcool et leurs utilisations
US8722082B2 (en) 2008-11-10 2014-05-13 Tekmira Pharmaceuticals Corporation Lipids and compositions for the delivery of therapeutics
EP3808177A1 (fr) 2008-11-10 2021-04-21 Arbutus Biopharma Corporation Nouveaux lipides et compositions d'administration d'agents thérapeutiques
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
CN104673798B (zh) 2008-12-03 2018-03-20 阿克丘勒斯治疗公司 UsiRNA复合物
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
WO2010080724A1 (fr) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Nanoparticules lipidiques inédites et composants inédits utilisables pour l'administration d'acides nucléiques
WO2010101870A1 (fr) 2009-03-03 2010-09-10 St. Jude Children's Research Hospital Compositions et méthodes de génération de lymphocytes t régulateurs induits par l'interleukine-35
CN102438978B (zh) 2009-03-20 2017-02-22 Clsn实验室股份有限公司 聚胺衍生物
WO2010127159A2 (fr) 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Micelles polymères pour l'encapsulation de polynucléotides
MX2011012597A (es) 2009-05-27 2012-04-19 Selecta Biosciences Inc Nanoportadores que poseen componentes con diferentes tasas de liberacion.
PL3431076T3 (pl) 2009-06-10 2022-01-31 Arbutus Biopharma Corporation Ulepszona formulacja lipidowa
JP5766188B2 (ja) 2009-07-01 2015-08-19 プロチバ バイオセラピューティクス インコーポレイティッド 固形腫瘍に治療剤を送達するための脂質製剤
KR101151415B1 (ko) 2009-07-10 2012-06-01 양지화학 주식회사 Ｃｃｒ２ 길항제로서의 피페라지닐에틸 3-아미노피롤리딘 유도체
US20110038871A1 (en) * 2009-08-11 2011-02-17 Veena Viswanth Ccr2 inhibitors for treating conditions of the eye
US9181295B2 (en) 2009-08-20 2015-11-10 Sirna Therapeutics, Inc. Cationic lipids with various head groups for oligonucleotide delivery
EA201290073A1 (ru) 2009-08-24 2013-01-30 Эсэпиен Фармасьютикалз, Инк. Соединения мочевины, содержащие 5,6-бициклический гетероарил, как ингибиторы киназ
US8828975B2 (en) 2009-09-25 2014-09-09 National Cheng-Kung University Phosphate-containing nanoparticle delivery vehicle
US8471004B2 (en) 2009-10-07 2013-06-25 Hoffman-La Roche Inc. Bicyclic compounds
EP2485770A4 (fr) 2009-10-08 2013-04-10 Merck Sharp & Dohme Nouveaux lipides cationiques à chaînes lipidiques courtes pour une administration d'oligonucléotides
WO2011050467A1 (fr) 2009-11-02 2011-05-05 Mold-Masters (2007) Limited Base de données pour moule à injection et intégration avec une machine de moulage par injection et des composants auxiliaires
BR112012016021A8 (pt) 2009-12-11 2018-06-12 Bind Biosciences Inc Formulações estáveis para liofilização de partículas terapêuticas
EA201290499A1 (ru) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. Композиции терапевтических полимерных наночастиц с высокой температурой стеклования и высокомолекулярными сополимерами
US8429390B2 (en) 2009-12-24 2013-04-23 Insyde Software Corp. Method for performing quick boot and general boot at bios stage
US9670487B2 (en) 2010-01-22 2017-06-06 Sirna Therapeutics, Inc. Cationic lipids for oligonucleotide delivery
PT2525815E (pt) 2010-01-24 2015-03-05 Novartis Ag Micropartículas de polímero biodegradável irradiadas
US20110262491A1 (en) 2010-04-12 2011-10-27 Selecta Biosciences, Inc. Emulsions and methods of making nanocarriers
US9285319B2 (en) 2010-04-21 2016-03-15 Riken Nucleic acid base analogs with quenching and fluorescent activities and applications thereof
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
CN106977603B (zh) 2010-05-04 2020-11-27 戊瑞治疗有限公司 结合csf1r的抗体
WO2011140294A1 (fr) 2010-05-07 2011-11-10 Swapsol Corp. Procédé et appareil pour éliminer des polluants d'un flux de gaz
US8802863B2 (en) 2010-05-24 2014-08-12 Sirna Therapeutics, Inc. Amino alcohol cationic lipids for oligonucleotide delivery
US8748667B2 (en) 2010-06-04 2014-06-10 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
TW201211027A (en) 2010-06-09 2012-03-16 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
MX2012014934A (es) 2010-06-17 2013-05-20 Janssen Pharmaceutica Nv Antagonistas de ciclohexilacetindinilo del receptor de la citocina quimioatrayente 2.
US20120000768A1 (en) 2010-07-02 2012-01-05 Primestar Solar, Inc. Methods for sputtering a resistive transparent buffer thin film for use in cadmium telluride based photovoltaic devices
DE102010032758B4 (de) 2010-07-29 2012-02-23 Fujitsu Technology Solutions Intellectual Property Gmbh Computersystem, Verfahren zum Programmieren einer Echtzeituhr und Computerprogrammprodukt
CN103025876A (zh) 2010-07-30 2013-04-03 库瑞瓦格有限责任公司 用于转染和免疫刺激的核酸与二硫化物交联的阳离子成分的复合体
WO2012016184A2 (fr) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour la délivrance d'agents actifs
MX2013001761A (es) 2010-08-24 2013-04-11 Gkn Driveline Int Gmbh Manguito para articulaciones, especialmente para articulaciones de velocidad constante, con area de transicion.
KR101878361B1 (ko) 2010-09-20 2018-08-20 시르나 쎄러퓨틱스 인코퍼레이티드 올리고뉴클레오티드 전달을 위한 신규 저분자량 양이온성 지질
US9029604B2 (en) 2010-09-30 2015-05-12 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
US9029590B2 (en) 2010-10-21 2015-05-12 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
EP2629760A4 (fr) 2010-10-22 2014-04-02 Bind Therapeutics Inc Nanoparticules thérapeutiques contenant des copolymères de masse moléculaire élevée
DK2635265T3 (en) 2010-11-05 2018-07-16 Sirna Therapeutics Inc New low molecular weight cyclic amine-containing cationic lipids for oligonucleotide delivery
AU2011323085B2 (en) 2010-11-05 2014-10-30 Miragen Therapeutics Base modified oligonucleotides
DE102011082231A1 (de) 2011-01-12 2012-07-12 Robert Bosch Gmbh Zündspule, insbesondere für kleinbauende Motoren
WO2012109121A1 (fr) 2011-02-07 2012-08-16 Purdue Research Foundation Nanoparticules glucidiques pour une efficacité prolongée d'un peptide antimicrobien
US20140005174A1 (en) 2011-03-17 2014-01-02 Anilkumar G. Nair Indole derivatives useful as ccr2 antagonists
EP2685828A4 (fr) 2011-03-17 2014-08-13 Merck Sharp & Dohme Dérivés de 3-azabicyclo[3.1.0]hexane substitués utiles en tant qu'antagonistes de ccr2
WO2012125663A2 (fr) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Dérivés d'amino cyclopentane substitués par cyclohexane en tant qu'antagonistes utiles de ccr2
CN103458879A (zh) 2011-03-25 2013-12-18 西莱克塔生物科技公司 渗透性介导释放型合成纳米载体
CA2834619A1 (fr) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Administration regulee d'immunosuppresseurs a partir de nanovecteurs synthetiques
CN103796680A (zh) 2011-06-21 2014-05-14 约翰霍普金斯大学 用于增强针对赘生物的基于免疫的治疗的聚焦放射
WO2013000922A1 (fr) 2011-06-27 2013-01-03 Universite Pierre Et Marie Curie (Paris 6) Peptides antagonistes de ccr2
CA2851155C (fr) 2011-10-14 2021-02-23 Ambit Biosciences Corporation Composes heterocycliques et procedes d'utilisation de ceux-ci
WO2013062134A1 (fr) 2011-10-25 2013-05-02 Fumihiko Ishikawa Procédé de production souris à système immunitaire humanisé
PE20181541A1 (es) 2011-10-27 2018-09-26 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
WO2013086354A1 (fr) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipides biodégradables pour l'administration d'agents actifs
WO2013111129A1 (fr) 2012-01-23 2013-08-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Hélices peptidiques stabilisées pour l'inhibition de la dimérisation du récepteur 2 de chimiokine de motif c (ccr2)
US8822460B2 (en) 2012-04-06 2014-09-02 Janssen Pharmaceutica Nv Fused cyclopentyl antagonists of CCR2
CA2877814A1 (fr) 2012-06-22 2013-12-27 Dingqiu HUANG Proteines de liaison a un antigene qui se lient a ccr2
AU2013290418B2 (en) 2012-07-19 2017-08-03 Chaozhong Cai Octahydro-cyclopentapyrrolyl antagonists of CCR2
CN106986952B (zh) 2012-08-17 2020-03-10 北卡罗来纳大学查珀尔希尔分校 水溶性的释放一氧化氮的聚葡糖胺和其用途
WO2014124329A1 (fr) 2013-02-08 2014-08-14 University Of Louisville Research Foundation, Inc. Nanoparticules pour l'administration de médicament
US10017741B2 (en) 2013-03-15 2018-07-10 Stemcell Technologies Inc. Compositions and methods for obtaining enriched mesenchymal stem cell cultures
US9365610B2 (en) 2013-11-18 2016-06-14 Arcturus Therapeutics, Inc. Asymmetric ionizable cationic lipid for RNA delivery
US9593077B2 (en) 2013-11-18 2017-03-14 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
DE102013112789B4 (de) 2013-11-19 2017-09-28 Phoenix Contact Gmbh & Co. Kg Transporthilfsvorrichtung sowie Anordnung mit einem aus elektromechanischen Bauelementen gebildeten Strang und einer entsprechenden Transporthilfsvorrichtung
AU2015236215B2 (en) 2014-03-25 2020-03-19 Arcturus Therapeutics, Inc. UNA oligomers having reduced off-target effects in gene silencing
JP6964410B2 (ja) 2014-06-23 2021-11-10 ファイヴ プライム セラピューティクス インク コロニー刺激因子１受容体（ｃｓｆ１ｒ）に結合する抗体で疾患を治療する方法
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
CN104168449B (zh) 2014-07-15 2017-06-20 阔地教育科技有限公司 一种跟踪区域切换控制方法及系统
ES2843586T3 (es) 2014-12-22 2021-07-19 Five Prime Therapeutics Inc Anticuerpos dirigidos contra CSF1R para tratar la SVNP
RS61531B1 (sr) 2015-04-13 2021-04-29 Five Prime Therapeutics Inc Kombinovana terapija za kancer
CN108135168B (zh) 2015-05-21 2021-07-20 凯莫森特里克斯股份有限公司 Ccr2调节剂
EP3216861A1 (fr) 2016-03-11 2017-09-13 Fropharm GmbH Cellules immunorégulatrices et leurs procédés de production

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140200259A1 (en) * 2006-02-23 2014-07-17 Novartis Ag RNAi-MEDIATED INHIBITION OF SELECT RECEPTOR TYROSINE KINASES FOR TREATMENT OF PATHOLOGIC OCULAR NEOVASCULARIZATION-RELATED CONDITIONS

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BÉGIN-LAVALLÉE VALÉRIE ET AL: "Functional inhibition of chemokine receptor CCR2 by dicer-substrate-siRNA prevents pain development", MOLECULAR PAIN, vol. 12, 15 June 2016 (2016-06-15), GB, XP055920896, ISSN: 1744-8069, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956154/pdf/10.1177_1744806916653969.pdf> DOI: 10.1177/1744806916653969 *
CORTNEY DEBRUIN ET AL: "Most purported antibodies to the human granulocyte colony-stimulating factor receptor are not specific", EXPERIMENTAL HEMATOLOGY, vol. 38, no. 11, 7 August 2010 (2010-08-07), pages 1022 - 1035, XP055140424, ISSN: 0301-472X, DOI: 10.1016/j.exphem.2010.07.011 *
D. E. SANFORD ET AL: "Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis", CLINICAL CANCER RESEARCH, vol. 19, no. 13, 30 June 2013 (2013-06-30), US, pages 3404 - 3415, XP055539775, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-13-0525 *
J. B. MITCHEM ET AL: "Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses", CANCER RESEARCH, vol. 73, no. 3, 5 December 2012 (2012-12-05), US, pages 1128 - 1141, XP055261087, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-12-2731 *
LEUSCHNER FLORIAN ET AL: "Silencing of CCR2 in myocarditis", EUROPEAN HEART JOURNAL, vol. 36, 20 June 2014 (2014-06-20), pages 1478 - 1488, XP055920899, Retrieved from the Internet <URL:https://academic.oup.com/eurheartj/article-pdf/36/23/1478/17050893/ehu225.pdf> *
LEUSCHNER FLORIAN ET AL: "Supplementary information: Therapeutic siRNA silencing in inflammatory monocytes in mice", NATURE BIOTECHNOLOGY, 9 October 2011 (2011-10-09), XP055921031, Retrieved from the Internet <URL:https://static-content.springer.com/esm/art%3A10.1038%2Fnbt.1989/MediaObjects/41587_2011_BFnbt1989_MOESM1_ESM.pdf> [retrieved on 20220513], DOI: 10.1038/nbt.1989 *
LEUSCHNER FLORIAN ET AL: "Therapeutic siRNA silencing in inflammatory monocytes in mice", NATURE BIOTECHNOLOGY, vol. 29, no. 11, 9 October 2011 (2011-10-09), New York, pages 1005 - 1010, XP055920900, ISSN: 1087-0156, Retrieved from the Internet <URL:https://www.nature.com/articles/nbt.1989.pdf> DOI: 10.1038/nbt.1989 *
See also references of WO2020033791A1 *
SHEN SONG ET AL: "Cationic Polymeric Nanoparticle Delivering CCR2 siRNA to Inflammatory Monocytes for Tumor Microenvironment Modification and Cancer Therapy", MOLECULAR PHARMACEUTICS, vol. 15, no. 9, 16 January 2018 (2018-01-16), US, pages 3642 - 3653, XP055920902, ISSN: 1543-8384, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.7b00997> DOI: 10.1021/acs.molpharmaceut.7b00997 *
ZHUANG HUIJIE ET AL: "CCL2/CCR2 axis induces hepatocellular carcinoma invasion and epithelial-mesenchymal transition in vitro through activation of the Hedgehog pathway", ONCOLOGY REPORTS, 2 November 2017 (2017-11-02), XP055920943, ISSN: 1021-335X, DOI: 10.3892/or.2017.6069 *

Also Published As

Publication number Publication date
EP3833762A1 (fr) 2021-06-16
WO2020033791A1 (fr) 2020-02-13
JP2021534101A (ja) 2021-12-09
US20210317461A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
EP3917497A4 (fr) Compositions oligonucléotidiques et procédés associés
EP3673055A4 (fr) Méthodes et compositions de ciblage d&#39;arn
EP3694530A4 (fr) Compositions d&#39;oligonucléotides et procédés associés
EP3664815A4 (fr) Compositions oligonucléotidiques et méthodes associées
EP3775203A4 (fr) Compositions d&#39;oligonucléotides et leurs procédés d&#39;utilisation
EP3638215A4 (fr) Formulations d&#39;arn
EP3737665A4 (fr) Promédicaments à base de kétamine, compositions et utilisations de ceux-ci
EP3790596A4 (fr) Compositions d&#39;oligonucléotides et leurs procédés d&#39;utilisation
EP3577127A4 (fr) Oligonucléotides ciblés
EP3723776A4 (fr) Compositions et méthodes pour supprimer des organismes pathogenes
EP3630199A4 (fr) Compositions d&#39;oligonucléotides et leurs procédés d&#39;utilisation
EP3630788A4 (fr) Compositions d&#39;oligonucléotides et leurs procédés d&#39;utilisation
EP3630789A4 (fr) Compositions d&#39;oligonucléotides et leurs procédés d&#39;utilisation
EP3532613A4 (fr) Méthodes et compositions pour le mappage d&#39;arn
EP3452596A4 (fr) Compositions d&#39;oligonucléotides et procédés associés
EP3833763A4 (fr) Oligonucléotides modifiés ciblant des snp
EP3245220A4 (fr) Procédés et compositions destinés au transfert de gènes ciblé
EP3500676A4 (fr) Procédés et compositions servant au transfert de gènes ciblés
EP3807644A4 (fr) Conjugués anticorps-oligonucléotide
EP3737400A4 (fr) Compositions et méthodes de ciblage de cancers exprimant clec12a
EP3833762A4 (fr) Compositions oligonucléotidiques pour cibler ccr2 et csf1r et leurs utilisations
EP4125815A4 (fr) Compositions thérapeutiques
EP3655440A4 (fr) Compositions et procédés de ciblage de cancers exprimant cd33
EP4010476A4 (fr) Oligonucléotides modifiés chimiquement ciblant des snp
EP3660153A4 (fr) Oligonucléotide simple brin

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40054967

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/713 20060101ALI20220523BHEP

Ipc: C12N 15/113 20100101AFI20220523BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20220831

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/713 20060101ALI20220825BHEP

Ipc: C12N 15/113 20100101AFI20220825BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230418